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Abstract
Background:  This  retrospective  single-institution  study  was  designed  to  describe  the  main  clin-
ical,  radiological  and  histological  features,  as  well  as  the  outcome  of  pregnancy-associated
breast cancer  (PABC),  with  a  special  emphasis  on  imaging  and  diagnostic  difﬁculties.
Material and  methods:  We  reviewed  all  breast  cancers  diagnosed  during  pregnancy  or  during
the  12  months  following  delivery  at  our  institution,  between  1993  and  2009.  Out  of  a  total  of
16,555  new  cases  of  breast  cancer  observed  during  this  period,  117  PABC  (0.7%)  were  diagnosed.
Results:  Mean  age  at  diagnosis  was  33.7  years.  Most  cancers  (81.2%)  were  diagnosed  after
delivery.  Intermediate  or  high  family  risk  was  frequent  (27.5%).  The  most  common  mode  of
presentation  was  a  palpable  mass  (89.7%).  Mean  time  to  diagnosis  was  5.8  months.  Sensitivity
for  mammography  was  80.9%  and  for  ultrasound  77%.  Most  prognostic  factors  were  unfavourable:
frequent  lymph  node  involvement  (51.8%),  high-grade  tumours,  hormone  receptor  negativity
(45.9%)  and  HER2  positivity  (38.7%).  Treatments  generally  included  surgery  (61.7%  mastec-
tomies),  radiotherapy  (96%)  and  chemotherapy  (79.6%).  Overall  5-year  survival  was  81.8%.
Conclusion:  PABC  is  an  uncommon  but  aggressive  form  of  breast  cancer  and  must  be  considered
in the  presence  of  any  breast  abnormality  during  pregnancy  or  the  months  following  delivery.
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Mammography  and  ultrasound  should  both  be  performed  at  the  slightest  clinical  suspicion.
Radiologists must  be  aware  that  masses  may  lack  typical  malignant  ultrasound  characteristics.
Biopsies should  be  largely  performed.
©  2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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pbbreviations
ABC  Pregnancy-associated  breast  cancer
NM  Tumor,  node,  metastasis
I-RADS  ACR  Breast  Imaging  Reporting  and  Data  System  of
the American  College  of  Radiology
OP Termination  of  pregnancy
CIS  Ductal  carcinoma  in  situ
DC  Invasive  ductal  carcinoma
LC  Invasive  lobular  carcinoma
ntroduction
regnancy-associated  breast  cancer  (PABC)  is  deﬁned  as  the
evelopment of  breast  cancer  during  pregnancy  or  during
he 12  months  following  delivery.  It  occurs  in  1/3000  to
/10,000 pregnancies  [1].  The  incidence  of  PABC  is  increas-
ng in  industrialized  countries,  as  women  tend  to  postpone
aternity [2].
PABC are  serious  cancers  for  several  reasons:  young  age  of
he patients,  frequently  delayed  diagnosis,  often  advanced
tage and  aggressive  histological  proﬁle,  although  whether
ABC is  more  serious  than  other  breast  cancers  at  an  equiv-
lent stage  and  with  equivalent  prognostic  factors  has  not
een clearly  determined  [3—5].
This  retrospective  study,  based  on  a  large  number  of  cases
ith long-term  follow-up,  was  designed  to  describe  the  main
linical, radiological,  and  histological  features,  as  well  as
he outcome  of  pregnancy-associated  breast  cancer,  with  a
pecial emphasis  on  imaging  and  diagnostic  difﬁculties.
aterials and methods
his  retrospective  descriptive  study  included  all  patients
ith breast  cancer  diagnosed  during  pregnancy  or  during
he 12  months  following  delivery  treated  at  René-Huguenin
ospital —  Institut  Curie  between  1st  January  1993  and  31st
ecember 2009.  The  study  was  approved  by  the  Curie
nstitute/René-Huguenin  Hospital  ethics  committee.
Out  of  a  total  of  16,555  new  cases  of  breast  can-
er observed  during  this  period,  including  1958  patients
etween the  ages  of  20  and  43  years,  117  cases  of  PABC
0.7%) were  diagnosed.
The study  population  comprised  113  patients,  including
 patients  with  synchronous  bilateral  breast  cancer,  i.e.  a
otal of  117  cancers.  Two  authors  (AL,  MM)  reviewed  all  of
he computerized  medical  charts.  The  imaging  was  most  of
he time  performed  in  various  external  institutions,  and  was
eviewed by  a  senior  breast-specialized  radiologist  of  our
nstitution in  73  of  the  117  cases.  When  mammography  and
m
t
aonography  had  not  been  reviewed  at  our  institution  and  the
maging was  no  longer  available  (44  cases,  mostly  from  1993
o 1999),  we  relied  on  the  medical  reports.  We  visualized
RI when  performed,  but  we  did  not  include  these  results
n this  study  as  they  concerned  only  15  patients.
The  following  elements  were  analysed:  clinical  setting
age at  diagnosis,  history),  date  of  diagnosis,  circumstances
f discovery,  clinical  examination  according  to  the  TNM  clas-
iﬁcation, inﬂammatory  signs  (erythema  and  oedema),  time
or diagnosis,  imaging  data  (mammography  and  ultrasound),
istological results,  treatment  regimen  and  follow-up.
We  established  the  familial  risk  for  breast  cancer  accord-
ng to  Eisinger  et  al.  [6]  We  considered  a  score  of  4  or  more
s high  risk,  a  score  of  3  or  2  as  intermediate  risk,  and  a
core of  1  as  not  signiﬁcant.
Imaging abnormalities  were  classiﬁed  according  to  the
riteria of  the  Breast  Imaging  Reporting  and  Data  System  of
he American  College  of  Radiology  (BI-RADS  ACR)  [7].  ACR
ategories 1,  2  and  3  were  considered  to  be  negative  and
CR categories  4  and  5  were  considered  to  be  positive.
Survival  analyses  were  performed  using  the
aplan—Meier method  with  R  2.10.1  software.
esults
he  study  population  comprised  113  patients,  four  of  whom
ad synchronous  bilateral  breast  cancer,  i.e.  a total  of  117
ancers. Most  results  are  presented  in  tables:  clinical  data
Tables 1  and  2),  imaging  (Table  3)  and  histology  (Table  4).
The  mean  age  at  diagnosis  was  33.7  years  (range:
4—42 years).
Out of  the  69  patients  for  whom  we  had  family  history
ata, 19  patients  (27.5%)  had  intermediate  or  high  risk  fac-
ors, the  other  50  patients  had  low  or  no  family  risk.
Eight  patients  (accounting  for  10  cases,  as  two  of  them
ad synchronous  bilateral  cancer)  out  of  the  113  patients
ad mutations  (3BRCA2  and  5BRCA1).  Only  one  patient  was
nown for  the  mutation  when  the  breast  cancer  was  diag-
osed, she  and  4  other  patients  were  at  high  risk.  One
utated (BRCA2)  patient  with  bilateral  breast  cancer  was
t intermediate  risk  and  2  patients  with  proven  mutations
ad no  familial  risk  (the  genetic  enquiry  was  done  because
f their  personal  history).
The  mean  time  from  ﬁrst  symptom  to  histological  diag-
osis was  5.8  months.
Among the  21  patients  in  whom  breast  cancer  was  diag-
osed during  pregnancy,  termination  of  pregnancy  (TOP)  was
erformed in  10  cases  (9/10  during  the  ﬁrst  trimester).Mammography  (Table  3)  showed  a  mass  (without  or  with
icrocalciﬁcations) in  55.1%  of  cases,  and  microcalciﬁca-
ions in  55%  of  cases  (isolated  or  associated  with  mass,
rchitectural distorsion  or  focal  asymmetry)  (Fig.  1).
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Table  1  Clinical  setting,  date  of  diagnosis  and  circum-
stances  of  discovery.
Variables  n  %
Familial  riska
Absent  or  low  50  72.5
Intermediate 9  13
High 10  14.5
Date of  diagnosis
During pregnancy  (mean  term:
3.9 months)
22 18.8
After pregnancy  95  81.2
≤ 12  months  after  delivery  80  68.4
> 12  months  after  delivery  (delayed
diagnosis)
6 5.1
≤ 12  months  after  TOP,  SM  or  FD  9  7.7
Circumstances of  discovery
Palpable mass  105  89.7
Subclinical lesion  (detected  on  imaging)  9  7.7
Inﬂammatory breast  2  1.7
Nipple discharge  1  0.9
TOP: termination of pregnancy, SM: spontaneous miscarriage,
FD  foetal death.
a Data available for 69 patients.
Table  2 TNM  classiﬁcation.
Ta Number  of
cases (%)
Nb n  (%)  M  n  (%)
T0  12  (10.7)  N0  57  (52.8)  MO  110  (94)
T1 20  (17.9)  N1  42  (38.9)  M1  7  (6)
T2 39  (34.8) N2  8  (7.4)
T3  27  (24.1)  N3  1  (0.9)
T4c 14  (12.5)
T: tumour size, N: lymph node involvement, M: metastases.
a Data available for 112 patients.
b Data available for 108 patients.
c Including 10 T4d cases.
Table  3  Type  of  abnormality  and  BI-RADS  classiﬁcation.
Variables  n  %
Mammographic
abnormalitiesa
Mass  (without/with
microcalciﬁcations)
49  (21/28)  55.1
Asymmetric density
(without/with  micros)
9  (3/6)  10.1
Architectural distorsion
(without/with  micros)
5  (5/0)  5.6
Isolated microcalciﬁcations 15  16.9
Normal 11  12.3
Mammographic classiﬁcation
ACR Bi-Rads  1/2/3  17  19.1
ACR Bi-Rads  4/5  72  80.9
Type of  ultrasound
abnormalityb
Mass  63  85.1
Isolated attenua-
tion/heterogeneous
zone
3  4.1
Normal 8  10.8
Ultrasound classiﬁcation
ACR Bi-Rads  1/2/3  17  23
ACR Bi-Rads  4/5  57  77
a Data available for 89 patients.
b Data available for 74 patients.
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patients derived  from  23  centres  in  France  [5]  and  anotherUltrasound  (Table  3)  was  usually  abnormal,  with  a  mass
or a  suspicious  focal  zone  in  89.2%  of  the  cases  (Fig.  2),  but
it was  sometimes  normal  and  some  masses  were  classiﬁed  as
probably benign  (ACR3),  because  of  regular  borders,  poste-
rior acoustic  enhancement,  or  parallel  orientation  (Fig.  3).
The  majority  of  patients  (90  out  of  113)  received
chemotherapy  (79,6%)  and  underwent  radiotherapy  (84,2%).
Neo-adjuvant chemotherapy  was  done  for  53  patients;  the
rest (37  patients)  had  adjuvant  chemotherapy.  Almost  all
patients (91.5%)  underwent  surgery  (except  those  who  pre-
sented with  metastatic  disease  at  diagnosis),  with  a  majority
of mastectomies  (61.7%)  because  of  tumor  size  and/or  mul-
tifocality.
Six patients  (seven  cancers)  presented  metastatic  disease
at diagnosis.  One  had  bone  metastasis,  one  had  nodal  (other
than axillary)  metastasis,  the  four  other  patients  had  mul-
tiple site  metastasis.  Three  of  them  had  died  and  the  other
three were  alive  at  the  end  of  the  study.
s
t
kThe  median  follow-up,  available  for  112  patients,  was
1 months  (range:  6—211  months).  Survival  curves  were  plot-
ed for  initially  M0  patients  (107  patients).
Five-year  survival  [95%  CI]  was:  81.8  [74.2;  90.1]  for  over-
ll survival,  56.5  [47.1;  67.7]  for  disease-free  survival,  74.4
65.7; 84.3]  for  locoregional  relapse-free  survival  and  72.5
63.8; 82.3]  for  metastasis-free  survival.
Twenty-three  of  the  107  (M0)  patients  died  and  46  expe-
ienced an  event:  15  experienced  isolated  local  relapse,  20
xperienced a  metastatic  event,  and  11  experienced  both
ocal relapse  and  a  metastatic  event.  Metastatic  events  con-
erned several  sites  in  53.3%  of  patients,  bone  only  in  16.7%,
iver only  in  10%,  and  other  sites  in  20%  of  cases.
iscussion
ABC  is  an  uncommon  disease,  as,  over  a  16-year  period
n our  institution,  it  represented  6%  of  all  breast  cancers
n the  20—43  years  age  group  (which  represent  only  11.8%
f all  breast  cancers).  This  proportion  is  consistent  with
hat reported  by  Andersson  et  al.  (7%),  while  Genin  et  al.
eported a  higher  proportion  (14.5%)  [2,8].
For  this  reason,  large  series  are  difﬁcult  to  obtain.  Many
tudies reported  in  the  literature  are  multi-institutional,
n particular,  the  study  by  Bonnier  et  al.,  comprising  154tudy of  130  PABC  diagnosed  during  pregnancy,  prospec-
ively collected  from  an  international  registry  [9].  To  our
nowledge, the  principal  single-institution  studies  reported
438  
Table  4  Histological  data.
Variables  n  %
Type  of  cancera
Invasive  ±  DCIS  95  84.1
DCIS +  micro-invasion  14  12.4
Pure DCIS  4  3.5
Invasive histological  typeb
Invasive  ductal  carcinoma  73  78.5
Invasive lobular  carcinoma 4 4.3
Other 16  17.2
Invasive component  gradec
Grade  1 4 4.2
Grade 2  31  32.6
Grade 3  60  63.2
In situ  graded
Low  grade  0  0
Intermediate grade  15  26.8
High-grade 41  73.2
Hormone receptorse
HR— 39  45.9
HR + 46  54.1
HER2f
HER2  positive 24  38.7
HER2 negative 38  61.3
Axillary lymph  nodesg
pN— 53  48.2
pN+ 57  51.8
Negative hormone receptors: ER— and PR—; positive hormone
receptors: ER+ and/or PR+.
a Data available for 113 cases.
b Data available for 93 cases.
c Data available for 95 cases.
d Data available for 56 cases.
e Data available for 85 cases.
f Data available for 62 cases.
g Data available for 110 cases (N+ on pre-chemotherapy cytology
or  axillary dissection).
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Five  of  these  cases  were  DCIS:  3  were  pure  DCIS,  one  wasn  the  literature  concerned  99  and  104  patients,  respectively
4,10], but  many  were  smaller  [11—15].
Most  of  the  breast  cancers  in  our  series  were  diagnosed
uring the  post-partum  period;  only  18.8%  were  diagnosed
uring pregnancy.  The  mean  age  of  onset  was  33.7  years,
hich is  consistent  with  the  data  reported  in  the  literature
16,17].
Like other  authors  [18—23],  we  frequently  found  an  inter-
ediate or  high  family  breast  cancer  risk  (27.5%).  Eight
atients out  of  the  113  (7%)  presented  a  BRCA1  or  BRCA2
utation (known  in  only  one  patient  at  the  time  of  diagno-
is, the  others  were  diagnosed  after  the  PABC  was  treated),
hich is  why  some  authors  recommend  genetic  screening  in
ll cases  of  PABC  [16].  This  seems  all  the  more  important  in
iew of  the  fact  that  in  our  study,  in  the  group  with  muta-
ions, two  patients  had  no  family  history  and  one  was  only  at
ntermediate risk.  However,  the  majority  of  the  young  PABC
atients did  not  have  a  signiﬁcant  family  history  of  breast
ancer and  this  diagnosis  must  therefore  be  considered  in
ll cases.
a
a
sA.  Langer  et  al.
The  most  common  mode  of  presentation  was  a  palpa-
le mass  (89.7%  in  our  series),  conﬁrming  the  data  of  the
iterature [12,14,16,22—25].  Nevertheless,  7.7%  of  lesions
9 cases)  in  our  series  were  subclinical.  Imaging  in  these
atients was  performed  systematically  because  of  high  or
ntermediate risk  (5  of  the  8  patients,  accounting  for  6
ases). In  two  cases,  imaging  was  performed  for  mastodynia
nd another  because  of  palpable  masses  due  to  cysts;  in
ll three,  mammography  showed  suspicious  microcalciﬁca-
ions.
PABC were  often  advanced  at  the  time  of  diagnosis,  as
igh rates  of  large  tumours  (T3  +  T4  =  36.6%),  clinical  lymph
ode involvement  (N1  +  N2  +  N3  =  47.2%)  and  inﬂammatory
esions (9%)  were  observed.  Other  authors  reported  similar
esults [4,5].
The mean  time  to  diagnosis  in  this  series  was  5.8  months,
imilar to  that  reported  by  most  authors  [12,22,26].  Delayed
iagnosis, deﬁned  as  an  interval  of  ≥  4  months  following
nset of  symptoms,  was  observed  for  40  (35.4%)  of  the  113
atients of  this  series,  with  a  severely  delayed  diagnosis
≥ 12  months)  for  15  patients  (13.3%).
There  are  many  causes  for  delayed  diagnosis.  Very  often,
either the  doctor  nor  the  patient  considers  the  possibility
f a  diagnosis  of  cancer,  particularly  during  pregnancy,  and
end to  defer  the  investigations  until  after  delivery.  Diag-
ostic difﬁculties  are  also  partly  responsible  for  delayed
iagnosis, as  clinical  examination  or  imaging  may  be  con-
idered to  be  benign  and  aspiration  cytology  may  give
alse-negative results.
Breast palpation  is  difﬁcult,  as  the  breasts  of  young
omen are  ﬁrmer,  more  nodular  and  hypertrophied,  partic-
larly during  pregnancy  and  lactation,  and  it  is  not  always
asy to  conﬁrm  palpation  of  a  mass;  breast  inﬂammation  can
lso  be  mistaken  for  simple  puerperal  mastitis.
Another  difﬁculty  comes  from  the  reluctance  of  many
octors to  request  mammography  for  young  women,  and
articularly during  pregnancy.  This  is  mostly  due  to  fear
f X-ray  related  risks.  But  mammography  has  been  demon-
trated to  be  a  safe  procedure,  even  during  pregnancy,  as
rradiation to  the  foetus  is  negligible  [14,27]  Many  think  that
ammography will  not  be  contributory  due  to  high  breast
ensity (related  to  the  patient’s  young  age  and  increased  by
regnancy or  post-partum).  Actually  the  mass  was  seen  in
5.1% of  our  cases,  and  even  when  the  mass  was  not  seen,
ammographic signs  in  favour  of  the  diagnosis  are  often
resent: microcalciﬁcations  in  55%  of  cases  in  our  series,
rchitectural distortion  (5.6%)  or  focal  asymmetry  (10.1%).
ammography had  a  high  sensitivity  in  our  study  (80.9%),
omparable to  that  described  by  Liberman  et  al.,  while  Ahn
t al.  and  Yang  et  al.  reported  sensitivities  of  86.7%  and  90%,
espectively [12,13,14].
Most  authors  consider  ultrasound  to  be  a very  reliable
xamination in  this  setting,  with  sensitivity  close  to  100%
12—15]. According  to  current  guidelines,  it  should  be  per-
ormed as  ﬁrst-line  procedure  [15,16].  However,  in  the
resent study,  the  sensitivity  of  ultrasound  was  lower,  with
n estimated  value  of  77%.  We  reviewed  carefully  the  17
ases with  ultrasound  ACR  1,  2  or  3.ssociated with  very  small  (2  and  3  mm)  invasive  components
nd another  with  micro-invasion,  which  explains  why  ultra-
ound was  negative.  In  4  of  these  cases,  we  found  typically
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Figure 1. A 29-year-old woman, 11 months post-partum, no family history. Left breast mass T2N1. (a) Mediolateral and (b) magniﬁed
mediolateral mammograms show architectural distorsion with irregular microcalciﬁcations highly suggestive of malignancy. Grade II invasive
ductal carcinoma.
Figure 2. A 38-year-old woman, 5 months pregnant, right breast
mass.  Ultrasound shows a mass with parallel orientation, posterior
acoustic  enhancement, but borders are microlobulated and lateral
Figure 3. A 39-year-old woman, high family risk, 7 months post-
partum.  Ultrasound shows small oval, benign-appearing left breast
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ypart  of the mass is irregular (ACR4). Grade III invasive ductal carci-
noma.
malignant  microcalciﬁcations  on  mammography,  and  the  5th
patient had  sero-hematic  nipple  discharge  with  multiple  ﬁll-
ing  defects  on  galactography.
Three  cases  were  due  to  small  (6—7  mm)  benign-
appearing masses  in  two  women  with  BRCA1  mutations  that
were at  histology  grade  3,  triple  negative  IDC  (Fig.  3).
Another case  was  particularly  misleading,  because  it
appeared as  a  subcutaneous  8  mm  ectopic  mobile  mass.
Both the  clinician  and  the  radiologist  thought  it  was  a  seba-
ceous cyst,  and  surgery  was  performed  at  the  request  of  the
patient, showing  a  6  mm  grade  1  IDC.
We think  those  9  cases  were  true  normal  (the  5  DCIS)  and
true ACR3  masses  (4  cases).
w
e
fass  (ACR3). Grade III invasive ductal carcinoma. Subsequent
enetic inquiry revealed BRCA1 mutation.
The  other  eight  cases  were  probably  incorrectly  clas-
iﬁed as  reassuring.  One  was  a  small  axillary  mass  in  a
7-year-old woman  who  had  previous  axillary  node  dissec-
ion for  bilateral  breast  cancer  three  years  before,  so,  the
xillary area  was  difﬁcult  to  examine  with  ultrasound  (MRI
as positive).  Another  case  was  a  huge  (100  mm)  inﬁltrating
nﬂammatory breast  cancer  in  a  patient  who  had  previous
reast surgery  reduction.  Ultrasound  was  considered  insuf-
ciently informative  (mammography  and  MRI  were  positive).
he most  frequent  situation  (6  out  of  8  cases)  was  a  mass  in  a
oung woman  ‘‘resembling  ﬁbro  adenoma’’.  Unfortunately,
e could  not  review  the  images  in  these  cases.  Ultrasound
xaminations were  derived  from  multiple  sources  and  dif-
erent machines,  and  patients  were  subsequently  referred
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o  our  institution.  For  the  present  study,  we  had  to  rely  on
he reports  when  the  imaging  had  not  been  reviewed.  It
s one  of  the  limitations  of  our  study,  but  it  also  is  note-
orthy, as  it  corresponds  to  the  ‘‘real-life’’  conditions  of
adiology practice.  Ayyappan  et  al.  [28]  have  reported  that
regnancy-associated breast  cancers  can  have  a  falsely  reas-
uring appearance  on  ultrasound  (parallel  orientation  in
8%, posterior  acoustic  enhancement  in  63%).  It  is  a  pitfall
adiologists must  be  aware  of.  Of  course,  the  young  patients’
ge can  also  be  misleading,  as  benign  pathologies  are  much
ore frequent  in  this  category.  If  those  8  cases  had  been
orrectly classiﬁed  ACR4  or  5,  in  an  ideal  set  without  mar-
in of  error,  ultrasound  sensitivity  would  have  been  at  best
7.8% which  is  much  better,  but  still  not  100%.
Thus,  the  low  sensitivity  of  ultrasound  in  our  study  is  due
o masses  incorrectly  classiﬁed  as  ‘‘probably  benign’’,  but
lso  to  DCIS,  and  to  classical  misleading  cancers  in  BRCA1
atients.
Most breast  disorders  related  to  pregnancy  are  benign,
ut given  the  seriousness  of  PABC  and  the  risk  of  a  delayed
iagnosis, all  masses  during  this  period  must  be  carefully
valuated. After  clinical  examination,  which  should  be  sys-
ematically and  regularly  performed  during  pregnancy,  US
s the  initial  test  in  symptomatic  women.  If  clinical  exam-
nation is  not  suspicious  and  US  aspect  is  typically  benign,
hort-term follow-up  may  be  considered.  But  in  case  of  high-
isk  women,  of  indeterminate  clinical  and/or  US  results,
ammography should  be  performed  without  hesitation.  We
ound  no  PABC  during  pregnancy  with  both  mammographic
nd US  negative  results.  In  cases  of  breast  inﬂammation,  if
t does  not  disappear  in  a  few  days  of  appropriate  medical
reatment, mammography  should  be  completed  quickly  by
iopsy.
Biopsies must  be  obtained  at  the  slightest  doubt.  Biopsy
s more  reliable  than  cytology  (high  false-negative  and  false-
ositive rates  during  pregnancy)  [28—30].
We  observed  a  similar  rate  of  invasive  ductal  carcinoma
o that  reported  in  the  literature  and  in  breast  cancer  in  gen-
ral, but  with  a  higher  rate  of  undifferentiated  carcinoma
3,5,16,18]. The  proportion  of  invasive  lobular  carcinoma
as lower  than  that  observed  in  breast  cancers  in  general
4.3% versus  10—15%)  and  pure  DCIS  was  uncommon  (3.5%
ersus 10  to  15%).
Most  prognostic  factors  were  unfavourable,  as  in  pre-
iously published  series,  with  a  majority  of  high-grade
umours for  the  invasive  component  (63.2%  grade  3)  and
or the  in  situ  component  (73.2%  high-grade)  and  frequent
ymph node  involvement  (51.8%)  [4,5,17,18,31].  Hormone
eceptors were  more  frequently  negative  in  PABC  than  in
ther breast  cancers  (45.9%  versus  about  30%),  in  line  with
he literature  [4,5,18,31,32].  However,  the  positive  hor-
one receptor  rate  may  be  underestimated  by  the  usual
echniques, especially  during  pregnancy,  which  is  why  some
uthors recommend  the  use  of  other  techniques  (pS2/TFF1)
o more  accurately  determine  hormone  dependence  and  to
ptimize endocrine  therapy  [11].
A  high  rate  of  HER2  positive  tumours  was  observed  in  this
eries (38.7%  versus  15%  for  most  series  of  breast  cancers),
s previously  reported  by  some  authors,  but  not  by  others
5,8]. However,  HER2  status  was  available  for  62  tumours
ut not  for  all,  as  this  series  began  in  1993,  and  HER2  status
as performed  routinely  only  from  2002.  The  unfavourable
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haracteristics  could  be  attributed  to  the  younger  age  of
omen with  PABC.  However,  a  recent  case-control  study
howed that  PABC  is  associated  with  unfavourable  histolog-
cal characteristics  independently  of  age  [4].
Due  to  poor  prognostic  factors  and/or  large  tumours,
he majority  of  patients  received  chemotherapy  (79,6%)  and
nderwent radiotherapy  (84,2%).  Almost  all  patients  under-
ent surgery  (except  those  who  presented  with  metastatic
isease at  diagnosis),  with  a  majority  of  mastectomies
61.7%) because  of  tumor  size  and/or  multifocality.
Five-year  overall  survival  for  M0  patients  was  81.8%.
hether the  prognosis  of  PABC  is  similar  to  that  of  other
reast cancers  when  matched  for  stage,  age  and  histology,
s still  debated  [4,5,9—11,17,18,23,26,33,34].
Numerous  oncological,  obstetric,  and  psychosocial
arameters must  be  taken  into  account  in  the  management
f pregnancy-associated  breast  cancer.  Termination  of  preg-
ancy (TOP)  does  not  improve  the  maternal  prognosis,  but
hould be  considered  case  by  case,  especially  at  the  begin-
ing of  pregnancy  and/or  in  the  presence  of  a  particularly
evere form  of  cancer  [9,35].  In  our  series,  many  patients
ad termination  of  pregnancy  (10  out  of  21).  The  diagno-
is in  those  cases  was  made  very  early  during  pregnancy:  7
imes during  the  ﬁrst  month  (pregnancy  was  sometimes  dis-
overed when  breast  cancer  was  being  assessed),  1  in  the
econd month  and  1  in  the  third  month.  The  only  patient  who
ad TOP  after  the  ﬁrst  trimester  (5th  month)  was  metastatic
t diagnosis.  For  patients  who  went  on  with  pregnancy,  no
dverse outcome  was  reported  for  the  baby  but  early  cae-
arean sections  were  frequent  (5  patients).
Surgery  can  be  performed  at  any  time  during  pregnancy,
adiotherapy and  endocrine  therapy  are  contraindicated,
nd chemotherapy  can  be  administered  from  the  second
rimester onwards,  the  main  risk  for  the  infant  being  pos-
ible preterm  delivery.  Most  studies  do  not  report  any
igniﬁcant toxicity  at  birth  following  maternal  chemother-
py, but  the  long-term  effects  of  chemotherapy  have  not
een extensively  studied.
Our  study  has  several  limitations.  Due  to  the  low  fre-
uency of  PABC,  this  large  series  spreads  over  16  years,
uring which  imaging  as  well  as  treatments  have  changed
 lot,  accounting  for  heterogeneity  in  both  these  issues.  We
id  not  study  the  role  of  MRI  (in  the  post-partum  period),
s only  15  patients  had  an  MRI.  But  we  found  that  clinical
xamination combined  with  ultrasound  and  mammography,
nd completed  by  biopsy  when  needed,  can  quickly  resolve
lmost all  cases.  MRI  will  probably  have  a  more  important
ole in  the  future,  if  not  for  diagnosis  itself,  at  least  in  a
eo-adjuvant treatment  setting  for  those  young  patients.
onclusion
lthough  infrequent,  PABC’s  incidence  is  growing,  as  the  age
f  ﬁrst  pregnancy  is  continuing  to  increase.  It  is  an  aggressive
orm of  breast  cancer,  with  unfavourable  histological  and
mmunophenotypic characteristics.  The  diagnosis  of  PABC
ust be  considered  in  the  presence  of  any  breast  abnormal-ty during  pregnancy  or  during  the  months  following  delivery,
ven in  the  absence  of  family  breast  cancer  history,  to  avoid
elayed diagnosis,  which  is  still  a  frequent  problem.  Imag-
ng should  be  performed  at  the  slightest  clinical  abnormality,
t  can
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[A  single-institution  study  of  117  pregnancy-associated  breas
as  mammography  and  ultrasound  are  both  contributory  and
complementary. Radiologists  must  be  aware  that  masses
may lack  typical  malignant  ultrasound  characteristics,  and
that ultrasound  can  be  negative  in  case  of  predominant  DCIS.
Biopsy must  be  preferred  to  cytology,  which  is  often  mislead-
ing in  this  setting.
Numerous parameters  must  be  taken  into  account  when
breast cancer  is  diagnosed  during  pregnancy  to  protect  the
foetus as  far  as  possible,  without  either  under-treating  or
delaying treatment  of  the  mother,  hence,  the  value  of  mul-
tidisciplinary referral  centres.
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